



COMPANY CONTACT:
investor@laterion.com
TEL: 510.350.7870

IATERION, INC. ANNOUNCES DR. LORIN K JOHNSON Ph.D., JOINS ITS BOARD OF DIRECTORS AND THE SCIENTIFIC ADVISORY BOARD

Lorin K. Johnson, Ph.D. Founder, Managing Director and Chief Scientist of Glycyx PharmaVentures, Ltd. has joined the Board of Directors and the Scientific Advisory Board of laterion, Inc. Dr. Johnson founded Salix Pharmaceuticals, Inc. in 1989 to develop novel, effective gastrointestinal therapies. In 2015 Salix was acquired by Bausch Health Companies, Inc. (NYSE/TSX: BHC) for an enterprise value \$15.8 billion. Prior to founding Salix Dr. Johnson was Director of Scientific Operations at California Biotechnology, Inc. Prior to joining the biopharmaceutical industry Dr. Johnson was an Assistant Professor of Pathology at Stanford School of Medicine. Lorin graduated with a B.S. and Ph.D. from the University of Southern California and was a post-doctoral researcher for molecular endocrinology at the University of California, San-Francisco.

“I’m enthusiastic to join laterion’s board of directors and the scientific advisory board for variety of reasons” said Dr. Lorin Johnson, Founder, Managing Director and Chief Scientist of Glycyx PharmaVentures, Ltd. “laterion capitalizes on 25 years of innovative academic and biopharmaceutical discoveries in the field of molecular endocrinology. I see great potential with laterion’s current drug candidates for Women’s Health as well as with their nuclear receptors modulating platform. Harnessing their discoveries for more selective hormone ligands and their reprogramming agents can alter the future of hormone therapies. This may result in more specific and safe therapies for multiple indications where steroid hormones are involved”.

laterion, Inc. identified multiple compounds with high potency and selectivity to modulate hormone activity. These drugs include receptor sub-type and tissue specific drugs as well as reprogramming agents which alter the natural hormone’s pharmacology.

“We are excited to add Dr. Johnson as a Board of Director and as a Scientific Advisory Board member” said Dr. Isaac Cohen, laterion’s CEO. “Dr. Johnson brings a wealth of knowledge and experience in the biopharmaceutical industry as a founder of companies and as an experienced board member. Lorin also shares extensive scientific knowledge and experience in the field of nuclear receptors. We believe his help will be fundamental to the company’s progress”.

“I’ve known Lorin for more than 30 years when I was his graduate student at Stanford University, and later as a post-doc at Dr. John Baxter’s laboratory at UCSF, where we were studying the molecular endocrinology of nuclear receptors” said Dr. Dale Leitman, M.D., Ph.D., laterion’s Chief Scientific Officer. “While I was focused on the estrogen receptor, Lorin focused on the glucocorticoid receptor. Our findings of the crosstalk between the





COMPANY CONTACT:
investor@iaterion.com
TEL: 510.350.7870

two receptors is exciting to our future collaboration in addressing multiple indications affected by these receptors and their hormones”.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Iaterion, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Iaterion, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

□□□